Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Daniel Bowles

Concepts (346)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Antineoplastic Agents
31
2026
2207
3.350
 Why?
Head and Neck Neoplasms
16
2023
562
2.840
 Why?
Salivary Gland Neoplasms
8
2023
39
2.810
 Why?
Protein Kinase Inhibitors
15
2026
980
2.220
 Why?
Carcinoma, Squamous Cell
14
2019
644
2.200
 Why?
Pyridines
14
2026
607
2.120
 Why?
Thyroid Neoplasms
9
2024
349
1.820
 Why?
Carcinoma, Non-Small-Cell Lung
9
2026
1188
1.690
 Why?
Molecular Targeted Therapy
7
2021
439
1.620
 Why?
Neoplasm Recurrence, Local
7
2023
1150
1.540
 Why?
Protein-Tyrosine Kinases
4
2021
431
1.420
 Why?
Antineoplastic Combined Chemotherapy Protocols
14
2024
1965
1.420
 Why?
Neoplasms
20
2024
2897
1.390
 Why?
Lung Neoplasms
11
2026
2664
1.370
 Why?
Anilides
6
2024
84
1.330
 Why?
Gonanes
7
2016
23
1.310
 Why?
Proto-Oncogene Proteins
6
2021
620
1.290
 Why?
Thyroid Carcinoma, Anaplastic
3
2020
36
1.240
 Why?
Cetuximab
7
2018
111
1.230
 Why?
Biomarkers, Tumor
8
2020
1321
1.200
 Why?
Adenocarcinoma
7
2024
923
1.180
 Why?
Phosphatidylinositol 3-Kinases
8
2017
380
0.800
 Why?
Pyrazoles
6
2026
517
0.780
 Why?
Mutation
13
2024
4093
0.740
 Why?
Carcinoma
3
2019
224
0.700
 Why?
Phytotherapy
2
2012
74
0.680
 Why?
Drugs, Investigational
2
2011
31
0.670
 Why?
Neoplasm Staging
15
2019
1468
0.660
 Why?
Cisplatin
6
2024
345
0.660
 Why?
Neoplasms, Second Primary
1
2021
102
0.610
 Why?
Papillomaviridae
4
2019
116
0.610
 Why?
Disease-Free Survival
10
2017
771
0.600
 Why?
Taxoids
3
2015
116
0.590
 Why?
Antineoplastic Agents, Immunological
2
2018
201
0.590
 Why?
Quinolines
5
2024
193
0.590
 Why?
Hedgehog Proteins
3
2015
200
0.580
 Why?
Carcinoma, Renal Cell
3
2017
234
0.580
 Why?
Pyrimidines
6
2026
520
0.570
 Why?
Humans
90
2026
145491
0.570
 Why?
Marijuana Smoking
2
2012
249
0.550
 Why?
Tumor Suppressor Proteins
2
2018
320
0.540
 Why?
Proto-Oncogene Proteins c-ret
5
2026
41
0.540
 Why?
Drug Resistance, Neoplasm
8
2024
881
0.540
 Why?
Middle Aged
44
2026
36176
0.510
 Why?
Kidney Neoplasms
3
2017
416
0.510
 Why?
Carcinoma, Mucoepidermoid
1
2017
17
0.510
 Why?
Colorectal Neoplasms
2
2016
866
0.500
 Why?
Aged
40
2026
26125
0.500
 Why?
Carcinoma, Transitional Cell
4
2017
69
0.490
 Why?
Ubiquitin Thiolesterase
1
2017
68
0.490
 Why?
Carcinoma, Ductal
1
2016
10
0.490
 Why?
Adenoma, Pleomorphic
1
2016
9
0.480
 Why?
Sulfones
2
2014
127
0.480
 Why?
Gene Rearrangement
2
2018
156
0.480
 Why?
Cannabinoids
2
2024
184
0.470
 Why?
Glycine
2
2014
186
0.460
 Why?
Maximum Tolerated Dose
5
2017
211
0.440
 Why?
Melanoma
1
2021
759
0.410
 Why?
Drug Interactions
6
2017
404
0.410
 Why?
Enzyme Inhibitors
3
2014
821
0.410
 Why?
Pyrroles
1
2014
213
0.390
 Why?
Iodine Radioisotopes
5
2024
137
0.390
 Why?
Gene Fusion
3
2023
30
0.390
 Why?
Signal Transduction
8
2018
5202
0.390
 Why?
Phenylurea Compounds
4
2024
119
0.380
 Why?
Receptor Protein-Tyrosine Kinases
2
2012
230
0.380
 Why?
Male
45
2026
72817
0.380
 Why?
Genetic Variation
1
2018
988
0.380
 Why?
Lymph Nodes
4
2017
502
0.370
 Why?
Indazoles
3
2019
83
0.360
 Why?
Aged, 80 and over
16
2026
8326
0.360
 Why?
Female
46
2026
78763
0.360
 Why?
Quinazolines
1
2013
266
0.350
 Why?
Class I Phosphatidylinositol 3-Kinases
4
2017
108
0.350
 Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
2012
127
0.340
 Why?
Treatment Outcome
15
2024
11831
0.340
 Why?
Antibodies, Monoclonal, Humanized
4
2024
994
0.330
 Why?
Neoplasm Metastasis
6
2021
691
0.320
 Why?
Adult
27
2026
40707
0.300
 Why?
Prognosis
9
2021
4323
0.280
 Why?
ErbB Receptors
4
2017
635
0.270
 Why?
Benzamides
3
2022
224
0.270
 Why?
Papillomavirus Infections
3
2022
343
0.260
 Why?
Pharmacogenomic Variants
2
2018
33
0.260
 Why?
Urologic Neoplasms
2
2017
31
0.250
 Why?
Nitriles
2
2022
205
0.250
 Why?
Carcinoma, Ductal, Breast
1
2007
89
0.250
 Why?
Mitoxantrone
1
2006
15
0.250
 Why?
Platinum
2
2024
50
0.240
 Why?
Xenograft Model Antitumor Assays
7
2024
929
0.240
 Why?
Enterobacter
1
2006
9
0.240
 Why?
Tooth Diseases
1
2006
13
0.240
 Why?
Esophageal and Gastric Varices
1
2006
36
0.230
 Why?
Gene Expression Profiling
5
2018
1769
0.230
 Why?
Enterobacteriaceae Infections
1
2006
42
0.230
 Why?
Salivary Glands
2
2023
36
0.230
 Why?
Oropharyngeal Neoplasms
2
2016
56
0.230
 Why?
Acute Kidney Injury
3
2018
873
0.220
 Why?
Animals
16
2024
38141
0.220
 Why?
Serotonin 5-HT3 Receptor Antagonists
1
2024
5
0.220
 Why?
Chemoradiotherapy
4
2020
239
0.220
 Why?
Proto-Oncogene Proteins B-raf
2
2024
224
0.220
 Why?
Clinical Trials as Topic
3
2018
1058
0.210
 Why?
Receptors, Estrogen
1
2007
400
0.210
 Why?
Cannabis
1
2011
509
0.210
 Why?
Antiemetics
1
2024
51
0.210
 Why?
Immunotherapy
2
2023
667
0.210
 Why?
Urinary Bladder Neoplasms
2
2017
260
0.200
 Why?
Liver Cirrhosis
1
2006
287
0.200
 Why?
Registries
2
2016
2410
0.200
 Why?
Carcinoma, Adenoid Cystic
1
2023
19
0.200
 Why?
Combined Modality Therapy
4
2018
1269
0.200
 Why?
Gene Expression Regulation, Neoplastic
3
2019
1439
0.200
 Why?
Bacteremia
1
2006
223
0.200
 Why?
Models, Biological
3
2024
1815
0.200
 Why?
Administration, Oral
3
2014
863
0.190
 Why?
Phenylthiohydantoin
1
2022
44
0.180
 Why?
Medical Marijuana
1
2024
122
0.180
 Why?
Survival Rate
5
2021
2093
0.170
 Why?
Radiation Pneumonitis
1
2021
31
0.170
 Why?
Drug Evaluation, Preclinical
2
2013
196
0.170
 Why?
Chemotherapy, Adjuvant
3
2017
427
0.170
 Why?
Survival Analysis
4
2020
1374
0.170
 Why?
Referral and Consultation
1
2007
862
0.170
 Why?
Carcinoma, Neuroendocrine
1
2021
37
0.160
 Why?
Disease Susceptibility
2
2020
343
0.160
 Why?
Adrenal Cortex Neoplasms
1
2021
69
0.160
 Why?
Adrenocortical Carcinoma
1
2021
71
0.160
 Why?
TOR Serine-Threonine Kinases
2
2016
452
0.160
 Why?
Gene Expression
2
2015
1478
0.160
 Why?
Cystectomy
2
2017
42
0.160
 Why?
SEER Program
1
2021
229
0.150
 Why?
Receptors, Nerve Growth Factor
1
2019
18
0.150
 Why?
Kaplan-Meier Estimate
3
2017
974
0.150
 Why?
DNA Mutational Analysis
2
2018
409
0.150
 Why?
Leukemia, Myeloid, Acute
1
2006
686
0.150
 Why?
Lymph Node Excision
2
2017
173
0.150
 Why?
Tracheal Neoplasms
1
2019
12
0.150
 Why?
Prostatic Neoplasms
1
2006
978
0.140
 Why?
Smad4 Protein
1
2019
33
0.140
 Why?
Positron Emission Tomography Computed Tomography
1
2020
117
0.140
 Why?
United States
8
2021
16115
0.140
 Why?
Alphapapillomavirus
2
2016
35
0.140
 Why?
Radiosurgery
1
2022
399
0.140
 Why?
Benzazepines
1
2018
35
0.140
 Why?
Genetic Heterogeneity
1
2019
65
0.140
 Why?
Risk
1
2021
917
0.140
 Why?
Genomics
3
2021
834
0.140
 Why?
Disease Management
2
2020
654
0.140
 Why?
Chromosome Aberrations
1
2019
164
0.140
 Why?
DNA Mismatch Repair
1
2018
53
0.130
 Why?
Tissue Fixation
1
2017
36
0.130
 Why?
Paraffin Embedding
1
2017
31
0.130
 Why?
Smokers
1
2018
137
0.130
 Why?
Oncogenes
1
2018
118
0.130
 Why?
Erlotinib Hydrochloride
1
2017
72
0.130
 Why?
Formaldehyde
1
2017
64
0.130
 Why?
Nasopharyngeal Neoplasms
1
2017
21
0.130
 Why?
Gene Deletion
1
2019
392
0.130
 Why?
Radiotherapy, Intensity-Modulated
1
2018
142
0.130
 Why?
DNA, Neoplasm
1
2017
158
0.130
 Why?
Neoplasm Grading
1
2018
311
0.130
 Why?
Health Services Needs and Demand
1
2019
279
0.130
 Why?
Gene Frequency
1
2018
483
0.120
 Why?
Chemoradiotherapy, Adjuvant
1
2016
44
0.120
 Why?
Induction Chemotherapy
1
2017
87
0.120
 Why?
Salivary Ducts
1
2016
2
0.120
 Why?
Laryngeal Neoplasms
1
2016
36
0.120
 Why?
Palliative Care
2
2018
1017
0.120
 Why?
Muscle, Smooth
1
2017
153
0.120
 Why?
Carboplatin
1
2016
161
0.120
 Why?
Nomograms
1
2016
59
0.120
 Why?
Dose-Response Relationship, Drug
3
2017
2030
0.120
 Why?
Database Management Systems
1
2016
50
0.120
 Why?
Hospice and Palliative Care Nursing
1
2018
115
0.120
 Why?
Prospective Studies
7
2024
8039
0.120
 Why?
Patient Navigation
1
2018
126
0.110
 Why?
Disease Progression
4
2018
2862
0.110
 Why?
Population Surveillance
1
2019
485
0.110
 Why?
Young Adult
5
2021
14192
0.110
 Why?
Angiopoietin-1
1
2015
12
0.110
 Why?
Computational Biology
2
2018
687
0.110
 Why?
Angiopoietin-2
1
2015
15
0.110
 Why?
Radiotherapy
1
2016
205
0.110
 Why?
Incidence
2
2019
2915
0.110
 Why?
Bone Neoplasms
1
2017
256
0.110
 Why?
Genetic Testing
1
2018
480
0.110
 Why?
Zinc Finger Protein GLI1
1
2014
26
0.110
 Why?
Retrospective Studies
8
2021
17269
0.110
 Why?
Retreatment
1
2014
79
0.110
 Why?
Hospice Care
1
2018
226
0.110
 Why?
Breast Neoplasms
1
2007
2373
0.110
 Why?
Response Evaluation Criteria in Solid Tumors
1
2014
21
0.110
 Why?
Piperazines
2
2018
378
0.100
 Why?
Neoplasms, Unknown Primary
1
2014
20
0.100
 Why?
Proto-Oncogene Proteins c-akt
1
2016
436
0.100
 Why?
Neoplastic Stem Cells
1
2018
409
0.100
 Why?
Paclitaxel
1
2015
256
0.100
 Why?
High-Throughput Nucleotide Sequencing
1
2017
553
0.100
 Why?
Patient Satisfaction
1
2018
710
0.100
 Why?
Veratrum Alkaloids
1
2013
20
0.100
 Why?
Promoter Regions, Genetic
1
2018
1247
0.100
 Why?
ras Proteins
1
2014
151
0.100
 Why?
Sulfonamides
1
2017
581
0.100
 Why?
Proportional Hazards Models
4
2017
1332
0.100
 Why?
Proto-Oncogene Proteins p21(ras)
1
2014
254
0.100
 Why?
PTEN Phosphohydrolase
1
2014
164
0.100
 Why?
Cell Cycle Proteins
2
2014
631
0.090
 Why?
Pilot Projects
2
2015
1896
0.090
 Why?
Imatinib Mesylate
1
2012
77
0.090
 Why?
Recombinant Fusion Proteins
1
2015
667
0.090
 Why?
Dasatinib
1
2012
57
0.090
 Why?
Risk Assessment
2
2019
3759
0.090
 Why?
Smoking
1
2019
1468
0.090
 Why?
Thiazoles
1
2012
139
0.090
 Why?
Hematopoietic Stem Cells
1
2015
419
0.090
 Why?
Aniline Compounds
1
2012
122
0.090
 Why?
Biomarkers
3
2018
4283
0.090
 Why?
Proto-Oncogene Proteins c-met
1
2012
76
0.090
 Why?
Biological Availability
1
2011
144
0.090
 Why?
Evidence-Based Medicine
2
2012
738
0.080
 Why?
Phosphatidylinositol 3-Kinase
1
2011
24
0.080
 Why?
Imidazoles
1
2012
246
0.080
 Why?
Mice
7
2024
18338
0.080
 Why?
Vascular Endothelial Growth Factor A
2
2024
550
0.080
 Why?
Adolescent
5
2022
22485
0.080
 Why?
Propensity Score
3
2017
376
0.080
 Why?
Tumor Microenvironment
1
2015
737
0.080
 Why?
Cell Line, Tumor
4
2024
3537
0.080
 Why?
Phenotype
1
2018
3157
0.080
 Why?
Algorithms
1
2018
1855
0.080
 Why?
Genetic Predisposition to Disease
1
2018
2355
0.080
 Why?
Kidney
1
2017
1498
0.070
 Why?
Receptors, Vascular Endothelial Growth Factor
2
2024
108
0.070
 Why?
Multivariate Analysis
3
2017
1544
0.070
 Why?
Adaptation, Psychological
1
2014
718
0.070
 Why?
Brain Neoplasms
1
2018
1329
0.070
 Why?
Axilla
1
2007
51
0.070
 Why?
Clinical Trials, Phase I as Topic
2
2019
50
0.060
 Why?
Cohort Studies
4
2022
5992
0.060
 Why?
Neoadjuvant Therapy
2
2022
466
0.060
 Why?
Sentinel Lymph Node Biopsy
1
2007
117
0.060
 Why?
RNA, Messenger
1
2014
2820
0.060
 Why?
Transcription Factors
1
2014
1733
0.060
 Why?
Ligation
1
2006
91
0.060
 Why?
Mastectomy
1
2007
181
0.060
 Why?
Pain
1
2011
787
0.060
 Why?
Receptors, Progesterone
1
2007
243
0.060
 Why?
Stress, Psychological
1
2014
1153
0.060
 Why?
Creatinine
2
2018
513
0.060
 Why?
Fatal Outcome
1
2006
306
0.060
 Why?
Lymphatic Metastasis
2
2017
335
0.060
 Why?
Neoplasm Invasiveness
2
2017
505
0.060
 Why?
Caregivers
1
2014
1070
0.060
 Why?
Granisetron
1
2024
6
0.060
 Why?
Quinuclidines
1
2024
11
0.050
 Why?
Ondansetron
1
2024
19
0.050
 Why?
Double-Blind Method
2
2021
2060
0.050
 Why?
Skin Neoplasms
1
2012
850
0.050
 Why?
Isoquinolines
1
2024
44
0.050
 Why?
Gastrointestinal Hemorrhage
1
2006
138
0.050
 Why?
Risk Factors
1
2019
10874
0.050
 Why?
Neoplasm Proteins
1
2007
441
0.050
 Why?
Oncogene Proteins, Fusion
1
2026
212
0.050
 Why?
Glomerular Filtration Rate
2
2018
765
0.050
 Why?
Demography
2
2015
287
0.050
 Why?
Vascular Endothelial Growth Factor Receptor-2
1
2023
86
0.050
 Why?
Benzimidazoles
1
2024
187
0.050
 Why?
Recurrence
2
2018
1142
0.050
 Why?
Databases, Factual
2
2019
1500
0.040
 Why?
Four-Dimensional Computed Tomography
1
2021
38
0.040
 Why?
Androgen Antagonists
1
2022
92
0.040
 Why?
Immunohistochemistry
2
2018
1710
0.040
 Why?
Pulmonary Ventilation
1
2021
82
0.040
 Why?
Receptors, Androgen
1
2022
148
0.040
 Why?
Quality of Life
1
2013
3195
0.040
 Why?
Radiotherapy Planning, Computer-Assisted
1
2021
149
0.040
 Why?
Receptor, trkC
1
2019
10
0.040
 Why?
Receptor, trkA
1
2019
18
0.040
 Why?
Clinical Trials, Phase II as Topic
1
2019
76
0.040
 Why?
Receptor, trkB
1
2019
39
0.040
 Why?
Trastuzumab
1
2019
117
0.040
 Why?
Extracellular Signal-Regulated MAP Kinases
1
2020
174
0.040
 Why?
Radiotherapy, Image-Guided
1
2018
39
0.030
 Why?
In Situ Hybridization, Fluorescence
1
2019
324
0.030
 Why?
Phthalazines
1
2018
63
0.030
 Why?
Organic Cation Transporter 2
1
2017
8
0.030
 Why?
Glutathione S-Transferase pi
1
2017
10
0.030
 Why?
Retroperitoneal Space
1
2017
18
0.030
 Why?
Organic Cation Transport Proteins
1
2017
25
0.030
 Why?
Urinary Diversion
1
2017
13
0.030
 Why?
Tumor Cells, Cultured
1
2019
883
0.030
 Why?
National Cancer Institute (U.S.)
1
2017
54
0.030
 Why?
Social Work
1
2018
85
0.030
 Why?
Membrane Glycoproteins
1
2019
496
0.030
 Why?
Margins of Excision
1
2017
51
0.030
 Why?
Immunophenotyping
1
2018
320
0.030
 Why?
Hospitals, Veterans
1
2018
259
0.030
 Why?
Laryngectomy
1
2016
17
0.030
 Why?
Kidney Function Tests
1
2017
156
0.030
 Why?
Oncologists
1
2017
47
0.030
 Why?
Cation Transport Proteins
1
2017
118
0.030
 Why?
Viral Core Proteins
1
2016
22
0.030
 Why?
Carcinogenesis
1
2018
227
0.030
 Why?
Pelvis
1
2017
126
0.030
 Why?
Regression Analysis
1
2018
1001
0.030
 Why?
Heart
1
2020
626
0.030
 Why?
Disease Models, Animal
2
2018
4559
0.030
 Why?
Radiotherapy, Adjuvant
1
2016
223
0.030
 Why?
Internationality
1
2016
156
0.030
 Why?
Random Allocation
1
2016
366
0.030
 Why?
Antibodies, Monoclonal
1
2022
1511
0.030
 Why?
Antibodies, Neoplasm
1
2015
34
0.030
 Why?
Anti-Bacterial Agents
1
2006
1953
0.030
 Why?
Biopsy, Large-Core Needle
1
2014
15
0.030
 Why?
Myocardium
1
2020
932
0.030
 Why?
Robotic Surgical Procedures
1
2017
183
0.030
 Why?
Analysis of Variance
1
2017
1304
0.030
 Why?
Bone Marrow
1
2015
307
0.020
 Why?
Receptor, Notch2
1
2013
15
0.020
 Why?
Receptor Cross-Talk
1
2013
21
0.020
 Why?
Receptor, Notch1
1
2013
63
0.020
 Why?
Psychiatric Status Rating Scales
1
2014
539
0.020
 Why?
Metabolic Clearance Rate
1
2012
115
0.020
 Why?
Pandemics
1
2021
1706
0.020
 Why?
Gene Silencing
1
2013
202
0.020
 Why?
Nausea
1
2012
113
0.020
 Why?
Logistic Models
1
2017
2130
0.020
 Why?
Transcriptome
1
2018
1038
0.020
 Why?
Area Under Curve
1
2012
329
0.020
 Why?
Needs Assessment
1
2014
401
0.020
 Why?
Vomiting
1
2012
132
0.020
 Why?
Mice, Nude
1
2013
678
0.020
 Why?
Diarrhea
1
2012
194
0.020
 Why?
Blotting, Western
1
2013
1162
0.020
 Why?
Drug Administration Schedule
1
2012
782
0.020
 Why?
Cell Proliferation
1
2017
2499
0.020
 Why?
Fatigue
1
2012
364
0.020
 Why?
Time Factors
1
2019
7171
0.020
 Why?
Age Factors
1
2016
3340
0.020
 Why?
Lung
1
2021
4103
0.020
 Why?
Colorado
1
2018
4572
0.020
 Why?
Cytokines
1
2015
2054
0.020
 Why?
Follow-Up Studies
1
2016
5426
0.020
 Why?
Surveys and Questionnaires
1
2018
6070
0.010
 Why?
Cross-Sectional Studies
1
2014
5891
0.010
 Why?
Bowles's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (346) concept(s)
_
Co-Authors Expand Description
See all (69) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)